Ken Griffin Enanta Pharmaceuticals Inc Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$10.05 - $16.54 $23,115 - $38,042	2,300 Added 100.0%	4,600 $47,000
Q2 2024 Aug 14, 2024	SELL	$11.43 - $17.02 $11,430 - $17,020	-1,000 Reduced 30.3%	2,300 $29,000
Q1 2024 May 15, 2024	SELL	$10.08 - $17.46 $3,024 - $5,238	-300 Reduced 8.33%	3,300 $57,000
Q4 2023 Feb 14, 2024	BUY	$8.18 - $10.78 $17,178 - $22,638	2,100 Added 140.0%	3,600 $33,000
Q3 2023 Nov 14, 2023	BUY	$11.09 - $22.13 $6,654 - $13,278	600 Added 66.67%	1,500 $16,000
Q2 2023 Aug 14, 2023	SELL	$20.68 - $39.85 $16,544 - $31,880	-800 Reduced 47.06%	900 $19,000
Q1 2023 May 15, 2023	SELL	$38.82 - $54.59 $69,876 - $98,262	-1,800 Reduced 51.43%	1,700 $68,000
Q4 2022 Feb 14, 2023	SELL	$40.77 - $53.73 $525,933 - $693,117	-12,900 Reduced 78.66%	3,500 $162,000
Q3 2022 Nov 14, 2022	BUY	$48.29 - $71.27 $791,956 - $1.17 Million	16,400 New	16,400 $851,000

110

21.1M

4.8K

4.6K

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $177M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.